Technology areas: Biotechnology & Pharmaceuticals • Communications
16 pending office actions • 13 art units • 15 examiners • 0 of 16 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Sloan-Kettering Institute for Cancer Research has 16 pending office actions in Biotechnology & Pharmaceuticals. Those matters span 15 examiners and 13 art units, indicating a broad prosecution footprint with limited examiner concentration. The portfolio’s technical issues are therefore likely to require matter-specific analysis rather than one uniform response approach.
JUEDES, AMY E is the busiest examiner, with 2 pending actions. That concentration is modest relative to the full portfolio, but the two matters may offer a useful point for comparing examiner treatment of claim scope, prior art, and written-description positions. Organizing the remaining actions by art unit can help preserve consistency while accommodating different examination practices.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (12%) |
| §103 only | 5 (31%) |
| §112 only | 2 (12%) |
| Double-patenting + other | 3 (19%) |
| Multi-statute (no §101) | 4 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 2 | 44.7% | +41.9% |
| KY, KEVIN | 1 | 77.4% | +25.0% |
| SHARIFF, MICHAEL ADAM | 1 | 79.7% | +24.4% |
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
| HANSEN, CONNOR LEVI | 1 | 72.7% | +38.4% |
| WRIGHT, ERIC BRANDON | 1 | 0.0% | +0.0% |
| ROBERTS, RACHEL L | 1 | 73.0% | +24.0% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| BAUSCH, SARAE L | 1 | 29.7% | +45.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840416 | METHODS FOR TREATING CANCER PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY BASED ON TEMPLATED INSERTIONS | ROCHELLE, CIERRA MARIE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18998107 | SYSTEMS AND METHODS FOR AUTOMATED TUMOR SEGMENTATION IN RADIOLOGY IMAGING USING DATA MINED LINE ANNOTATIONS | KY, KEVIN | — |
| 18838097 | AUTOMATED CHROMOGENIC IN SITU HYBRIDIZATION QUANTIFICATION AND IMMUNOHISTOCHEMICAL ASSESSMENT FROM WHOLE SLIDE IMAGES | HANSEN, CONNOR LEVI | — |
| 18708163 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | JUEDES, AMY E | — |
| 18706831 | EPIGENETIC TARGETS IN CLONAL HEMATOPOIESIS | WRIGHT, ERIC BRANDON | — |
| 18565767 | METHODS FOR PREDICTING AND TREATING CHEMORESISTANCE IN SMALL CELL LUNG CANCER PATIENTS | BAUSCH, SARAE L | — |
| 18285925 | NADK2 INHIBITION IN CANCER AND FIBROTIC DISORDERS | VAN BUREN, LAUREN K | — |
| 18554176 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | JOHANSEN, PETER N. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18998107 | SYSTEMS AND METHODS FOR AUTOMATED TUMOR SEGMENTATION IN RADIOLOGY IMAGING USING DATA MINED LINE ANNOTATIONS | KY, KEVIN | — |
| 18881208 | DETERMINING PREDICTED OUTCOMES OF SUBJECTS WITH CANCER BASED ON SEGMENTATIONS OF BIOMEDICAL IMAGES | SHARIFF, MICHAEL ADAM | — |
| 18838097 | AUTOMATED CHROMOGENIC IN SITU HYBRIDIZATION QUANTIFICATION AND IMMUNOHISTOCHEMICAL ASSESSMENT FROM WHOLE SLIDE IMAGES | HANSEN, CONNOR LEVI | — |
| 18708163 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | JUEDES, AMY E | — |
| 18705228 | SYSTEMS AND METHODS FOR GENERATING A CORRECTED PLANAR SCINTIGRAPHY IMAGE (CPSI) | ROBERTS, RACHEL L | — |
| 18703318 | ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | DUFFY, BRADLEY | — |
| 18690228 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | LEE, WILLIAM Y | — |
| 18565767 | METHODS FOR PREDICTING AND TREATING CHEMORESISTANCE IN SMALL CELL LUNG CANCER PATIENTS | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1644 | 3 |
| 2672 | 2 |
| 2671 | 1 |
| 1627 | 1 |
| 1632 | 1 |
| 2674 | 1 |
| 1643 | 1 |
| 1623 | 1 |
| 1699 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18998107 | SYSTEMS AND METHODS FOR AUTOMATED TUMOR SEGMENTATION IN RADIOLOGY IMAGING USING DATA MINED LINE ANNOTATIONS | KY, KEVIN | 2671 | §102§103 | Non-Final OA | — | Pending | Jan 23, 2025 |
| 18881208 | DETERMINING PREDICTED OUTCOMES OF SUBJECTS WITH CANCER BASED ON SEGMENTATIONS OF BIOMEDICAL IMAGES | SHARIFF, MICHAEL ADAM | 2672 | §103 | Non-Final OA | — | Pending | Jan 03, 2025 |
| 18840416 | METHODS FOR TREATING CANCER PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY BASED ON TEMPLATED INSERTIONS | ROCHELLE, CIERRA MARIE | 1627 | §103 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18838097 | AUTOMATED CHROMOGENIC IN SITU HYBRIDIZATION QUANTIFICATION AND IMMUNOHISTOCHEMICAL ASSESSMENT FROM WHOLE SLIDE IMAGES | HANSEN, CONNOR LEVI | 2672 | §102§103 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18708163 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | JUEDES, AMY E | 1644 | §101§102§103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18706831 | EPIGENETIC TARGETS IN CLONAL HEMATOPOIESIS | WRIGHT, ERIC BRANDON | 1632 | §103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18705228 | SYSTEMS AND METHODS FOR GENERATING A CORRECTED PLANAR SCINTIGRAPHY IMAGE (CPSI) | ROBERTS, RACHEL L | 2674 | §103 | Final Rejection | — | Pending | Apr 26, 2024 |
| 18703318 | ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | DUFFY, BRADLEY | 1643 | §103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18690228 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18565767 | METHODS FOR PREDICTING AND TREATING CHEMORESISTANCE IN SMALL CELL LUNG CANCER PATIENTS | BAUSCH, SARAE L | 1699 | §112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18285925 | NADK2 INHIBITION IN CANCER AND FIBROTIC DISORDERS | VAN BUREN, LAUREN K | 1638 | §102§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18554184 | COMBINATION THERAPY WITH DEXAMETHASONE AND TUMOR-SPECIFIC T CELL ENGAGING MULTI-SPECIFIC ANTIBODIES FOR TREATING CANCER | BENAVIDES, JENNIFER ANN | 1675 | §103§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18554176 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | JOHANSEN, PETER N. | 1644 | §101§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18550914 | METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS | JUEDES, AMY E | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18350454 | METHODS AND COMPOSITIONS FOR SENSITIZING PRC2 MUTANT TUMORS TO IMMUNE CHECKPOINT BLOCKADE THERAPY | ALAM, DANYAL HASSAN | 1672 | §103 | Final Rejection | 8d overdue | Pending | Jul 11, 2023 |
| 17427502 | DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS | LEE, HOI YAN NMN | 1693 | §103DP | Non-Final OA | — | Pending | Jul 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSloan-Kettering Institute for Cancer Research has 16 pending office actions as of October 2026, spread across 13 art units and 15 examiners.
Amy E Juedes has the most, with 2 of Sloan-Kettering Institute for Cancer Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
